Chrysin suppress immune responses and protects from experimental autoimmune encephalomyelitis in mice

Area of Science:

• Neuroimmunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Experimental autoimmune encephalomyelitis (EAE) serves as a key animal model for studying MS pathogenesis.
• Understanding the molecular mechanisms underlying EAE is crucial for developing effective MS therapies.

Purpose of the Study:

• To investigate the therapeutic potential of chrysin in a mouse model of multiple sclerosis (EAE).
• To elucidate the effects of chrysin on key molecular targets and inflammatory pathways in EAE.

Main Methods:

• EAE was induced in C57BL/6 mice using the myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide.
• Mice were treated with chrysin to evaluate its impact on clinical symptoms and disease progression.
• Histone deacetylase (HDAC) activity, glycogen synthase kinase-3β (GSK-3β) levels, and pro-inflammatory cytokine levels were assessed.
• Histone acetyltransferase 3 and 4 (HAT3, HAT4) levels were also measured.

Main Results:

• Chrysin treatment significantly reduced weight loss and attenuated clinical signs of EAE.
• Chrysin administration blunted the EAE-induced increase in histone deacetylase (HDAC) activity and glycogen synthase kinase-3β (GSK-3β) levels.
• Chrysin reduced the levels of pro-inflammatory cytokines associated with EAE.
• The compound counteracted the EAE-induced decrease in histone acetyltransferases 3 and 4 (HAT3, HAT4).

Conclusions:

• Chrysin demonstrates significant beneficial effects in the EAE model of multiple sclerosis.
• Chrysin may exert its therapeutic effects by modulating HDAC and HAT activities and inflammatory pathways.
• These findings highlight chrysin as a potential therapeutic agent and identify specific molecular targets for future MS drug development.